Seeking Alpha

An FDA panel has voted 12-1 against expanded use of Amgen's (AMGN -1.2%) Xgeva for prostate...

An FDA panel has voted 12-1 against expanded use of Amgen's (AMGN -1.2%) Xgeva for prostate cancer bone met prevention, according to a Bloomberg report. (pdf)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs